Kidney failure

Hemodialysis Market to Reach $111.8 Billion, Globally, by 2032 at 3.8% CAGR: Allied Market Research

Retrieved on: 
Wednesday, November 22, 2023

PORTLAND, Ore., Nov. 22, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Hemodialysis Market By Product And Service (Equipments, Consumables, Drugs, and Services),  Type (Conventional Hemodialysis, Daily Hemodialysis, and Nocturnal Hemodialysis), and Dialysis Site (In-Center Dialysis and Home Dialysis): Global Opportunity Analysis and Industry Forecast, 2023–2032" According to the report, the global hemodialysis industry generated $76.9 billion in 2022 and is anticipated to generate $111.8 billion by 2032, witnessing a CAGR of 3.8% from 2023 to 2032.

Key Points: 
  • This can hinder their ability to invest in R&D, product innovation, and market expansion.
  • Furthermore, the recession does not affect the demand for hemodialysis products & services and pharmaceuticals, as hemodialysis serves as a life-saving treatment for patients with kidney failure.
  • By type, the services segment held the highest market share in 2022, accounting for nearly two-thirds of the global hemodialysis market revenue and is estimated to maintain its leadership status during the forecast period, owing to the high adoption of hemodialysis services, and the high number of hemodialysis service provider.
  • The consumables segment is projected to attain the highest CAGR of 4.8% from 2023 to 2032, owing to increase in usage of hemodialysis consumables by hemodialysis patients and surge in demand for hemodialysis consumables.

Holiday Pet Dangers

Retrieved on: 
Wednesday, November 15, 2023

MINNEAPOLIS, Nov. 15, 2023 /PRNewswire/ -- The holidays are best spent with family and friends, not taking a trip to the animal hospital. With the trifecta of Thanksgiving, Christmas and New Years Eve coming up, the toxicology experts at Pet Poison Helpline want to warn pet lovers about the many dangers that face pets during this festive season.

Key Points: 
  • With the trifecta of Thanksgiving, Christmas and New Years Eve coming up, the toxicology experts at Pet Poison Helpline want to warn pet lovers about the many dangers that face pets during this festive season.
  • Meinke also contacted Pet Poison Helpline, who then worked with the medical team at BluePearl to identify the lily, diagnose and treat his pets.
  • "Many holiday treats include chocolate, and are often left sitting out on counters and dinner tables," said Dr. Schmid.
  • This year, we want pet lovers to remember the holidays for all the joy and happiness, not an emergency room visit."

ACADEMY OF NUTRITION AND DIETETICS COMMENDS LEGISLATION TO INCREASE ACCESS TO CARE FOR PEOPLE WITH PREDIABETES

Retrieved on: 
Wednesday, November 8, 2023

Chicago, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The Academy of Nutrition and Dietetics commends U.S. Sens.

Key Points: 
  • Chicago, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The Academy of Nutrition and Dietetics commends U.S. Sens.
  • Medicare covers screening for participants with Type 2 diabetes and medical nutrition therapy for those with diabetes, but not those with prediabetes.
  • A recent study by the Academy of Nutrition and Dietetics published in T he American Journal of Clinical Nutrition confirmed the value of registered dietitian nutritionists and the effectiveness of medical nutrition therapy in addressing prediabetes.
  • “The Academy calls on Congress to pass this important bill to ensure Medicare participants with prediabetes have access to the care they deserve.”
    Representing more than 112,000 credentialed nutrition and dietetics practitioners, the Academy of Nutrition and Dietetics is the world’s largest organization of food and nutrition professionals.

Alucent Biomedical Receives Regulatory Approval for Second U.S. Clinical Study

Retrieved on: 
Tuesday, November 7, 2023

Alucent Biomedical Inc. today announced that the U.S. Food & Drug Administration (FDA) granted an Investigational Device Exemption (IDE) for a U.S. clinical study of its AlucentNVS technology for promoting the maturation of arteriovenous fistulas (AVF) in patients requiring hemodialysis.

Key Points: 
  • Alucent Biomedical Inc. today announced that the U.S. Food & Drug Administration (FDA) granted an Investigational Device Exemption (IDE) for a U.S. clinical study of its AlucentNVS technology for promoting the maturation of arteriovenous fistulas (AVF) in patients requiring hemodialysis.
  • The milestone follows Alucent’s first IDE approval from the FDA, which was granted in August 2023.
  • AlucentNVS combines an intravascular device with a photochemical process to link structural proteins in the wall of a blood vessel to control vascular remodeling.
  • The intervention is designed to promote patency of the vessel’s lumen and establish sustained improvement of blood flow.

Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Friday, November 3, 2023

SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced additional data from two pivotal clinical studies demonstrating sparsentan has the potential to preserve kidney function and significantly delay time to kidney failure compared to an active comparator, suggesting long-term benefits in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). Data from the Phase 3 PROTECT and DUPLEX Studies were presented as late-breaking oral presentations at the American Society of Nephrology (ASN) Kidney Week 2023 and simultaneously published in The Lancet (PROTECT) and The New England Journal of Medicine (DUPLEX).

Key Points: 
  • Data from the Phase 3 PROTECT and DUPLEX Studies were presented as late-breaking oral presentations at the American Society of Nephrology (ASN) Kidney Week 2023 and simultaneously published in The Lancet (PROTECT ) and The New England Journal of Medicine (DUPLEX) .
  • The absolute overall change in kidney function from baseline to the end of the study for patients treated with FILSPARI was -5.8 mL/min/1.73m2 compared to -9.5 mL/min/1.73m2 with irbesartan.
  • Treatment with FILSPARI demonstrated lower rates of the composite endpoint of 40% decline in eGFR, kidney failure or death compared to irbesartan.
  • Sparsentan showed a consistent and sustained achievement of complete remission of proteinuria in 18.5% of patients on sparsentan vs. 7.5% for irbesartan.

Keiretsu Forum’s Investor Capital Expo Highlights Resilience and Opportunity in Early-Stage Investments

Retrieved on: 
Monday, October 30, 2023

Despite this backdrop, the 11th Annual Investor Capital Expo in Philadelphia on October 25, 2023, drew the participation of 200 forward-thinking accredited angel investors attending in person and virtually.

Key Points: 
  • Despite this backdrop, the 11th Annual Investor Capital Expo in Philadelphia on October 25, 2023, drew the participation of 200 forward-thinking accredited angel investors attending in person and virtually.
  • Keynote, Ron Weissman , Chair of the Angel Capital Association counselled participants that short-term demand for capital exceeds supply but, that this market correction is not a collapse.
  • Keiretsu Forum Mid-Atlantic and South-East is coming off of three consecutive years of record breaking angel member investments.
  • For more information on upcoming investor meetings and company presentations, contact Keiretsu Forum Mid-Atlantic and South-East at [email protected]

Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis

Retrieved on: 
Thursday, November 2, 2023

Results from an analysis of kidney biopsy samples collected from patients participating in the AURORA Clinical Program were presented in an oral session.

Key Points: 
  • Results from an analysis of kidney biopsy samples collected from patients participating in the AURORA Clinical Program were presented in an oral session.
  • Activity scores for both arms improved to a similar degree, while the chronicity scores remained stable in both arms.
  • “The results presented at ASN this week demonstrate important clinical and mechanistic findings associated with LUPKYNISⓇ treatment.
  • Following is the complete guide to Aurinia’s presentations at ASN 2023:
    Title: Comparison of dual-immunosuppressive therapy and a voclosporin-based, triple-immunosuppressive regimen for lupus nephritis: a propensity analysis of ALMS and AURORA 1 studies

Novel AI-Driven Model Validated to Predict Risk of Chronic Kidney Disease Progression in Large U.S. Study

Retrieved on: 
Saturday, November 4, 2023

Using data from a diverse population of over 4 million U.S. adults, the model was more than 80% accurate in predicting CKD progression over a five-year period.

Key Points: 
  • Using data from a diverse population of over 4 million U.S. adults, the model was more than 80% accurate in predicting CKD progression over a five-year period.
  • These findings were presented in an oral session at the American Society of Nephrology (ASN) Kidney Week conference in Philadelphia, being held from November 1-5, 2023.
  • Physicians need novel tools to evaluate risk of CKD progression, which could assist with earlier diagnosis and treatment."
  • The Klinrisk model was developed to predict the risk of CKD progression, defined as either a 40% decline in estimated glomerular filtration rate (eGFR) or kidney failure (dialysis, kidney transplant or eGFR below 10 mL/min/1.73 m2).

Global Dialysis Market Set for Impressive Growth, Projected to Reach US$107.96 Billion by 2023 with a Strong CAGR of 4.80% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 25, 2023

The global dialysis market is on track to achieve substantial growth, with projections indicating it will reach an impressive value of US$107.96 billion by 2023, supported by a robust CAGR of 4.80% over the forecast period.

Key Points: 
  • The global dialysis market is on track to achieve substantial growth, with projections indicating it will reach an impressive value of US$107.96 billion by 2023, supported by a robust CAGR of 4.80% over the forecast period.
  • The services segment currently holds the largest market share, while consumables are anticipated to exhibit the highest growth with a significant CAGR.
  • By Type: The global dialysis market is segmented into Hemodialysis and Peritoneal Dialysis.
  • The global dialysis market is divided into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

DaVita Collaborates with Google Cloud to Develop Customized Clinical Operating System Designed to Transform Kidney Care

Retrieved on: 
Wednesday, October 18, 2023

SUNNYVALE, Calif., Oct. 18, 2023 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) and Google Cloud today announced that the organizations have collaborated to create a new clinical operating system that sets a foundation for streamlined kidney care for more than 200,000 DaVita patients.

Key Points: 
  • Kidney care provider harnesses the power of Google Cloud's leading-edge infrastructure, AI, and analytics tools to help improve care plans and streamline clinical workflows
    SUNNYVALE, Calif., Oct. 18, 2023 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) and Google Cloud today announced that the organizations have collaborated to create a new clinical operating system that sets a foundation for streamlined kidney care for more than 200,000 DaVita patients.
  • With the deployment, DaVita has moved from a decentralized clinical documentation system to a unified platform that leverages data from more than 30 million dialysis treatments per year to generate insights designed to help improve clinical outcomes.
  • Ultimately, the platform is designed to support DaVita's mission to provide integrated kidney care that helps, improve patient quality of life, and lower the cost of care.
  • A leader in kidney care, DaVita has more than 20 years of clinical data, based on the more than 30 million dialysis treatments the organization administers each year.